Our top pick for
TCR2 Therapeutics Inc is a biotechnology business based in the US. TCR2 Therapeutics shares (TCRR) are listed on the NASDAQ and all prices are listed in US Dollars. TCR2 Therapeutics employs 109 staff and has a market cap (total outstanding shares value) of USD$899.1 million.
|Latest market close||USD$31.68|
|52-week range||USD$5.84 - USD$30|
|50-day moving average||USD$23.3336|
|200-day moving average||USD$18.3241|
|Wall St. target price||USD$35.56|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-10.673|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-09)||N/A|
|1 month (2020-12-16)||N/A|
|3 months (2020-10-16)||N/A|
|6 months (2020-07-16)||N/A|
|1 year (2020-01-16)||N/A|
|2 years (2019-01-16)||N/A|
|3 years (2018-01-16)||N/A|
|5 years (2016-01-16)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-18.08%|
|Return on equity TTM||-29.04%|
|Market capitalisation||USD$899.1 million|
TTM: trailing 12 months
There are currently 1.9 million TCR2 Therapeutics shares held short by investors – that's known as TCR2 Therapeutics's "short interest". This figure is 21.9% up from 1.6 million last month.
There are a few different ways that this level of interest in shorting TCR2 Therapeutics shares can be evaluated.
TCR2 Therapeutics's "short interest ratio" (SIR) is the quantity of TCR2 Therapeutics shares currently shorted divided by the average quantity of TCR2 Therapeutics shares traded daily (recently around 300437.51962323). TCR2 Therapeutics's SIR currently stands at 6.37. In other words for every 100,000 TCR2 Therapeutics shares traded daily on the market, roughly 6370 shares are currently held short.
However TCR2 Therapeutics's short interest can also be evaluated against the total number of TCR2 Therapeutics shares, or, against the total number of tradable TCR2 Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case TCR2 Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 TCR2 Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0758% of the tradable shares (for every 100,000 tradable TCR2 Therapeutics shares, roughly 76 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against TCR2 Therapeutics.
Find out more about how you can short TCR2 Therapeutics stock.
We're not expecting TCR2 Therapeutics to pay a dividend over the next 12 months.
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include TC-210, mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which initiated in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignancies. Its product candidates in pipeline focuses on adult acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma areas. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.